ArticleAmerican journal of translational research2022
Curable congestive heart failure in patients with primary aldosteronism: two cases reports.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Aldosterone fuels the progression of cardiovascular-kidney -metabolic syndrome: focus on primary aldosteronism spectrum.Endocrine · 2026Review
- Establishment and evaluation of a patient-derived organoids-based xenograft model of primary aldosteronism using [Journal of translational medicine · 2025Article
- Immunohistochemistry confirms pulmonary metastases from an adrenal adenocarcinoma causing primary hyperaldosteronism in a cat.JFMS open reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary aldosteronism (PA) is characterized by overproduction of aldosterone which can lead to various target organ damage, including the cardiovascular system. There are rare case reports about PA patients with severe heart failure. We report two male patients who were admitted because of severe cardiac systolic dysfunction induced by primary aldosteronism. Their cardiac function improved significantly after target therapy. Patient A was a 33 year old male with serum aldosterone concentration (PAC) 251.3 pg/ml, renin activity (PRA) 0.04 ng/ml/h, and aldosterone-to-renin ratio (ARR) 627.5. Computed tomography (CT) revealed a tumor in the left adrenal gland, while no dominant secretion function was found in the left side after the adrenal veins sampling (lateralization index 0.99). Bilateral adrenal hyperplasia was diagnosed and spironolactone was prescribed. Left ventricular ejection fraction (LVEF) was improved from 30% to 45% at the 11-month follow-up visit. Patient B was 43 years old male with PAC 185.5 pg/ml, PRA 0.46 ng/ml/h and ARR 403.2; Captopril challenge test was positive and a microadenoma (2.7*3.2*2.8 cm) was revealed on CT. Unilateral aldosterone-producing adenoma was diagnosed. His LVEF was improved from 30% to 51% at 12 months after laparoscopic adrenalectomy. Thus, it is important to screen for PA in patients with heart failure and launch the appropriate treatment for such patients.
Indexed as
Identifiers
35559375PMC9091133What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.